Artificial Intelligence
PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) — PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce it has entered into an exclusive research collaboration agreement with Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for unmet medical needs, to expand Revive’s development plans with psilocybin to treat cancer and to discover novel uses of undisclosed psychedelic compounds.
PharmaTher recently announced the filing of a U.S. provisional patent application outlining the potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™, PharmaTher’s proprietary drug repurposing artificial intelligence platform. The patent application, entitled “Use of Psilocybin in the Treatment of Cancers”, outlines psilocybin’s potential use for Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia.
“We are excited to partner with Revive Therapeutics on our psilocybin cancer program and on panaceAI™ to unlock the potential novel uses of psychedelic compounds in diseases that have sub-optimal or no treatment options,” said Fabio Chianelli, CEO of PharmaTher Inc. “We have been focused on advancing the clinical development of ketamine in the treatment of Parkinson’s disease, while also discovering novel uses of psychedelics using panaceAI™ with the aim to partner these developments. The partnership with Revive allows us to focus on expanding our ketamine programs such as the combination of ketamine with an FDA approved drug and the delivery of ketamine via our proprietary microneedle delivery technology targeting large market opportunities in depression, post-operative and neuropathic pain and disorders of the brain and nervous system.”
The research collaboration with Revive is PharmaTher’s first partnership with panaceAI™ and it validates PharmaTher’s business model in discovering novel uses of psychedelics and partnering these discoveries with life sciences companies seeking to expand their product pipeline with psychedelics.
“Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach,” said Michael Frank, CEO of Revive. “We are excited to advance the development of PharmaTher’s recent discovery in the potential of psilocybin to treat certain cancers and leveraging PharmaTher’s panaceAI™ discovery AI platform to discover new uses of undisclosed psychedelic compounds to expand our psychedelics drug pipeline.”
The collaboration will give Revive the exclusivity to advance the research of psilocybin in the treatment of cancer and leverage PharmaTher’s panaceAI™ psychedelic discovery AI platform to screen, identify and evaluate undisclosed psychedelic compounds directed at pre-specified targets for use with Revive’s drug delivery technology.
About PharmaTher Inc.
PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. PharmaTher repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our goal is to advance the commercialization of panaceAI™, our drug repurposing artificial intelligence platform, and our ketamine focused product pipeline in the treatment of Parkinson’s Disease, depression, and pain. Learn more at: PharmaTher.com and follow us on Facebook, Twitter and LinkedIn.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.
For more information, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Inc.
Tel: 1-888-846-3171
Email: [email protected]
Website: www.pharmather.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Newscope Capital Corporation’s (the “Company) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to U.S. patent application of psilocybin to treat cancer, psychedelic drug repurposing, drug combinations and discovery, U.S. Food and Drug Administration (“FDA”) approval, panaceAI™, psilocybin and ketamine programs towards human clinical studies under the FDA regulatory pathway and product developments. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on the Company’s profile at www.sedar.com.
Artificial Intelligence
AI In Life Science Analytics Market worth $3.56 Bn by 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
JERSEY CITY, N.J., May 2, 2024 /PRNewswire/ — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global AI In Life Science Analytics Market – By Component (Software, Hardware, Services), By Deployment (On-premise, Cloud), By Application (Research and Development, Sales and Marketing support, Supply chain analytics), By End-user (Medical Devices, Pharmaceutical, Biotechnology)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global AI In Life Science Analytics Market is valued at US$ 1.63 Bn in 2023, and it is expected to reach US$ 3.56 Bn by 2031, with a CAGR of 10.39% during the forecast period of 2024-2031.
Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/2456
AI in the context of life science analytics refers to the use of AI techniques and tools for the analysis of biological as well as environmental data. With the use of artificial intelligence (AI), life science analytics may make better use of complex healthcare, medical, and scientific information by applying high-level computational algorithms.
The goal of life science analytics is to find useful patterns in massive amounts of medical, clinical, and biological data by applying various data analysis tools and techniques. Because of its superior computing and learning capabilities, AI is indispensable in improving life science analytics. The demand for more accurate and tailored techniques in healthcare and the life sciences, together with the rising availability of data, is projected to propel artificial intelligence in the life science analytics market to new heights as the discipline undergoes more development.
Pharmaceutical spending on complex diseases like cancer is on the rise, which is fueling the expansion of artificial intelligence in the life science analytics industry. However, implementing artificial intelligence (AI) solutions can be prohibitive for smaller organizations, making investing in the necessary technology and training difficult.
List of Significant Players in the AI In Life Science Analytics Market:
IndegeneLexalyticsDatabricksSAS Institute Inc.SisenseIQVIAIBMSorcero AtomwiseNuMediiAiCure LLCNuance CommunicationsAPIXIO, IncInsilico MedicineOther Market PlayersAI In Life Science Analytics Market Report Scope:
Report Attribute
Specifications
Market Size Value In 2023
USD 1.63 Bn
Revenue Forecast In 2031
USD 3.56 Bn
Growth Rate CAGR
CAGR of 10.39 % from 2024 to 2031
Quantitative Units
Representation of revenue in US$ Million and CAGR from 2024 to 2031
Historic Year
2019 to 2023
Forecast Year
2024-2031
Report Coverage
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered
By Component, Application, Deployment, And End-Use
Regional Scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Market Dynamics:
Drivers-
The growing demand for AI in the life science analytics market is fueled by the exponential growth of data in the life sciences. Conventional methods of data analysis need to be revised in the face of the enormous amounts of biological, clinical, and healthcare data produced by genomics, proteomics, and electronic health records. Artificial intelligence (AI) has arisen as a game-changing solution because of its superior processing capabilities; it can handle and derive valuable insights from these immense and complicated datasets with ease. Incredible possibilities for pattern discovery, disease outcome prediction, and optimization of healthcare and life sciences research await in the mountains of data. Utilizing AI, researchers, healthcare experts, and pharmaceutical businesses can easily integrate and analyze various forms of data, which in turn allows them to uncover useful insights.
Challenges:
The prime challenge is a lack of awareness, a shortage of competent individuals, and a lack of norms and protocol because of lockdowns and isolation in emerging countries, which is predicted to slow the growth of AI in the life science analytics market. The low level of implementation of AI in several healthcare settings. There is no denying AI’s revolutionary promise in healthcare, yet smaller or less tech-savvy healthcare organizations face challenges when trying to integrate these new technologies. In these contexts, adoption is more gradual because of a lack of resources, including both financial commitment and trained staff. Implementing AI systems is complex, necessitating specialized training and infrastructure changes, which adds to the already existing difficulties. In addition, the health and life science sectors were helped by the COVID-19 epidemic. There was a dramatic uptick in the use of artificial intelligence (AI) for life science analytics as a response to the epidemic, which prompted the industry to speed up innovation in the face of such a dire threat. During the pandemic, markets worldwide grew because of AI-driven discoveries, not the months-long and similarly costly traditional methods of vaccine recognition.
Regional Trends:
The North American AI in life science analytics market is anticipated to record a large market share in terms of revenue. It is projected to grow at a high CAGR in the near future due to the high need for AI solutions in almost every field of life science. Artificial intelligence (AI) solutions for biotech, precision medicine, and drug development are in high demand in this country. Besides, Asia Pacific had a remarkable share in the market due to the fact that numerous research firms have ramped up their investments in artificial intelligence software and technology in an effort to boost operational efficiency.
Curious About This Latest Version Of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2456
Recent Developments:
In Feb 2024, Wipro and IBM extended their partnership in order to provide clients with new AI services and support. the Wipro enterprise ai-ready platform was developed by Wipro and IBM in the course of an extensive collaboration. The expanded collaboration merged the technological prowess and industry knowledge of Wipro with IBM’s pioneering hybrid cloud and AI developments. The objective was to develop collaborative solutions that facilitated the progress of integrating, enterprise-ready, dependable, and comprehensive artificial intelligence solutions.In Dec 2022, Quantori formed a partnership with Databricks to expedite data-driven advancements in the fields of life sciences and healthcare. Quantori created solutions using the Databricks Lakehouse Platform to offer immediate insights into real-world data to enhance patient outcomes for researchers and physicians.Segmentation of AI In Life Science Analytics Market-
By Component-
SoftwareHardwareServicesBy Deployment-
On-premiseCloudBy Application-
Research and DevelopmentSales and Marketing supportSupply chain analyticsOthersBy End-user-
Medical DevicesPharmaceuticalBiotechnologyBy Region-
North America-
The USCanadaMexicoEurope-
GermanyThe UKFranceItalySpainRest of EuropeAsia-Pacific-
ChinaJapanIndiaSouth KoreaSouth East AsiaRest of Asia PacificLatin America-
BrazilArgentinaRest of Latin America Middle East & Africa-
GCC CountriesSouth AfricaRest of the Middle East and AfricaFor More Customization @ https://www.insightaceanalytic.com/customisation/2456
Why should buy this report:
To receive a comprehensive analysis of the prospects for global AI In Life Science Analytics marketTo receive industry overview and future trends of global AI In Life Science Analytics marketTo analyze the AI In Life Science Analytics market drivers and challengesTo get information on the AI In Life Science Analytics market size value (US$ Mn) forecast till 2031Major Investments, Mergers & Acquisition in global AI In Life Science Analytics market industryOther Related Reports Published by InsightAce Analytic:
Life Science Tools Market
Big Data in Healthcare Market
Digital Twins in Healthcare Market
eConsent In Healthcare Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact US:InsightAce Analytic Pvt. Ltd.Tel.: +1 551 226 6109Email: [email protected] Visit: www.insightaceanalytic.comFollow Us on LinkedIn @ bit.ly/2tBXsgS
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ai-in-life-science-analytics-market-worth-3-56-bn-by-2031—exclusive-report-by-insightace-analytic-pvt-ltd-302134305.html
Artificial Intelligence
Fiix by Rockwell Automation Announces Industry-Leading GenAI Prescriptive Work Orders
Included in Fiix Asset Risk Predictor, Fiix Prescriptive Maintenance transforms asset health predictions into actionable work orders
BRUSSELS, May 2, 2024 /PRNewswire/ — Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, is excited to add cutting-edge, generative artificial intelligence (GenAI) prescriptive work orders to Fiix Asset Risk Predictor software, creating the first complete predictive and prescriptive maintenance solution to help manufacturers eliminate unplanned downtime.
Fiix Asset Risk Predictor’s powerful AI can be set up in as little as two weeks and starts predicting asset failures days in advance. With the addition of Fiix Prescriptive Maintenance, it now features GenAI capabilities that transform failure predictions into detailed, actionable work orders for maintenance teams.
Work orders are generated using asset data, completed work orders and trusted maintenance sources. Teams can then review and edit work orders, and instantly push them to any computerized maintenance management system (CMMS) or enterprise asset management (EAM) tool. All data is kept completely private and protected by the highest security standards.
“With Fiix Prescriptive Maintenance, you can turn asset data into the predictions and work orders you need to drastically reduce unplanned downtime, boost operational equipment effectiveness (OEE), and make better use of resources,” says Sandy D’Souza, senior director sales, Americas, Fiix by Rockwell Automation. “It also helps close the maintenance knowledge gap, ensuring everyone has access to detailed asset and work order information, whether they’ve just started their career or have decades of experience at a company.”
By bringing together AI-powered predictive maintenance and actionable GenAI work orders, Fiix Asset Risk Predictor ensures manufacturers see results in the fastest time possible.
Fiix Asset Risk Predictor, now including Fiix Prescriptive Maintenance, can be purchased and used independently from the Fiix CMMS or seamlessly integrated with it. It can also be integrated with any CMMS or EAM your company uses.
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 29,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
Photo – https://mma.prnewswire.com/media/2403493/ARP_LP_Hero_Phase_2_2x.jpgLogo – https://mma.prnewswire.com/media/1981317/Rockwell_Automation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fiix-by-rockwell-automation-announces-industry-leading-genai-prescriptive-work-orders-302134253.html
Artificial Intelligence
Breaking New Ground: Sentiance Introduces First Mobile Crash Detection for Motorcycles
ANTWERP, Belgium, May 2, 2024 /PRNewswire/ — Sentiance, a leader in road safety solutions, today announces a significant advancement in motorcycle safety with the expansion of its mobile Crash Detection technology. Originally developed for cars, this first-of-its-kind solution is now tailored specifically for motorcycles.
Built on state-of-the-art interpretive AI and machine learning models, Sentiance’s Crash Detection technology utilizes smartphone sensors and GPS data to analyze motion data in real-time. This enables the system to detect potential impacts with exceptional accuracy and reliability, addressing the unique dynamics of motorcycles. Unlike other systems, Sentiance’s technology operates directly on-device, ensuring a high level of privacy and data security.
“Today we see around 30% of all road crash deaths globally involving motorcycles, with countries like Thailand having an average of 5,000 motorcyclist deaths recorded annually. Ahead of the game, we’re not just enhancing safety features for those motorcycle riders, we are fundamentally transforming their safety landscape,” said Toon Vanparys, CEO of Sentiance. “This technology is not only a game-changer for individual safety but also addresses a significant need in markets where motorcycles are essential for daily transport and industries like food, grocery, and document delivery.”
This technology is especially crucial in regions like APAC, the Middle East, India, Africa, and South America, to transform road safety standards and make advanced safety tools easily accessible. Sentiance’s scalable and affordable technology ensures that even in cost-sensitive markets, safety, and privacy are not compromised.
By reducing accident response times and improving driving behaviors through data-driven insights, Sentiance’s mobile Crash Detection promises to reduce accident response times, saving lives and improving road conditions globally.
About Sentiance
Sentiance is the leader in motion insights. Our mission is to save lives every day and shape the future of road safety. Unlike telematics companies, we focus on the driver and not the vehicle because most accidents are caused by human error.
With our revolutionary on-device AI technology, companies use insights from The Edge Platform to produce scalable, cost-efficient, and privacy-centric solutions for their customers.
View original content:https://www.prnewswire.co.uk/news-releases/breaking-new-ground-sentiance-introduces-first-mobile-crash-detection-for-motorcycles-302133343.html
-
Uncategorized7 days ago
Cherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence6 days ago
Hikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence6 days ago
HITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence6 days ago
Web O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Artificial Intelligence6 days ago
Greater efforts urged on sci-tech cooperation
-
Artificial Intelligence5 days ago
Cognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Uncategorized6 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence6 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry